Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor
Gernot Langer(Bayer (Germany)), Stefan Bäurle(Bayer (Germany)), Ulrich Bothe(Bayer (Germany)), Christoffer Lind(Evotec (United Kingdom)), Alexis Laux‐Biehlmann(Bayer (Germany)), Beau le Roy(University of Zurich), Christiane Otto(German Cancer Research Center), Adam J. Davenport(Evotec (United Kingdom)), Horst Irlbacher(Nuvisan (Germany)), John Scott(Evotec (United Kingdom)), Jörg Müller(Bayer (Germany)), Katrin Nowak‐Reppel(Nuvisan (Germany)), Anne Schlüter(Evotec (Germany)), Mark Slack(University of Cambridge)
Cited by 3
Related Papers
The histamine H3 receptor as a therapeutic drug target for CNS disorders
|Drug Discovery Today|2009|181
Menstruation pulls the trigger for inflammation and pain in endometriosis
|Trends in Pharmacological Sciences|2015|145
Pulmonary Hypertension and Right Heart Failure in Pituitary Adenylate Cyclase–Activating Polypeptide Type I Receptor–Deficient Mice
|Circulation|2004|79
Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers
|Scientific Reports|2021|68
Chiral pyridylimidazolines: synthesis, arene ruthenium complexes and application in asymmetric catalysis
|Journal of the Chemical Society Perkin Transactions 1|2001|67